- ALLEGRA-D® 12 HOUR (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets and Drisdol (ergocalciferol) Capsules now available as authorized generics under the Winthrop label in the U.S.
CINCINNATI, OHIO; November 2, 2009 — Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label.  Fexofenadine HCl and pseudoephredrine HCl extended-release tablets and ergocalciferol capsules represent the first two products launched in the U.S. by Winthrop U.S. under the Winthrop label with Prasco providing sales support and distribution services to Winthrop U.S.  Prasco expects to begin shipping the products immediately. Specific financial terms of the agreements were not disclosed.

“We are especially proud to expand our relationship with sanofi-aventis U.S., and we are certainly pleased to provide pharmacists and consumers with these authorized generic options,” said Prasco Chief Executive Officer E. Thomas Arington.  “Consumers and pharmacists can have confidence in their prescription drug choices, when they have the identical product, quality, reliability of supply and the identical experience that only the brand can provide.”

ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis U.S.

About Prasco
Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience.  The company’s business model encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.  Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and warehouse facility including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.

###

Contact:
Jeff Zurcher
Prasco Laboratories

513-204-1275
media.relations@prasco.com
US.FEX.09.10.012